Allos Efaproxiral ENRICH Data Needed For Brain Metastases Approval
Executive Summary
Approval of Allos Therapeutics' oncologic Excelar (efaproxiral/RSR13) should await confirmatory efficacy data from an ongoing Phase III trial, an FDA advisory committee recommended May 3
You may also be interested in...
Allos Oncologic Efaproxiral Is “Approvable” Pending Phase III ENRICH Data
Approval of Allos' oncologic efaproxiral will need to await positive data from an ongoing Phase III study in patients with brain metastases originating from breast cancer, an FDA "approvable" letter states
Allos Oncologic Efaproxiral Is “Approvable” Pending Phase III ENRICH Data
Approval of Allos' oncologic efaproxiral will need to await positive data from an ongoing Phase III study in patients with brain metastases originating from breast cancer, an FDA "approvable" letter states
Genasense Progression-Free Survival Data Do Not Show “Real Effect,” Cmte.
Genta/Aventis Genasense appears to have a "real effect" on response rates in metastatic melanoma patients but not on progression-free survival or survival, FDA's Oncologic Drugs Advisory Committee concluded at its May 3 meeting